secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001104659-26-033885
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec posts record FY2025 PEDMARK sales $44.6M (+50% YoY); Q4 $13.8M (+75%)
----------------------------------------------------------------------------

- Full-year net product sales $44.6M vs $29.6M in 2024; Q4 $13.8M vs $7.9M in prior year.
- Net loss $10.1M in FY2025 vs $0.4M in 2024, driven by higher G&A and a $2.0M loss on debt extinguishment.
- Cash $36.7M at year-end; zero debt after paying down $21.5M term loan in Nov 2025.
- Completed oversubscribed equity offerings raising $42.0M net; expanded commercial team.
- Positive topline results from Japan trial; two institution-led studies initiated in testicular cancer and AYA patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465926033885/0001104659-26-033885-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465926033885/fencf-20260324x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-033885

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer